

# Parkinson's disease Unravelling Genetic Predisposition and Innovative Therapies

Priya Samuel\*

Department of Medicine, University of Kerala, Kerala, India

## Introduction

Parkinson's disease (PD) is a complex neurodegenerative disorder that primarily affects the motor system, leading to symptoms such as tremors, bradykinesia (slowness of movement), rigidity and postural instability. It is the second most common neurodegenerative disorder after Alzheimer's disease and its prevalence increases with age. While the exact cause of Parkinson's disease remains elusive, research has shown that both genetic and environmental factors play crucial roles in its development [1]. In recent years, advances in genetic research have significantly contributed to our understanding of the genetic predisposition to PD, offering insights into potential innovative therapeutic approaches.

## Genetic predisposition to Parkinson's disease

Genetic factors are estimated to contribute to about 10-15% of PD cases, with the majority of cases being sporadic and caused by a combination of genetic and environmental factors. However, the identification of specific genetic mutations has provided valuable insights into the underlying mechanisms of the disease [2,3].

**Alpha-Synuclein Gene (SNCA):** One of the most extensively studied genetic factors in PD is the alpha-synuclein gene (SNCA). Mutations in SNCA are linked to the familial form of PD, known as PARK1. These mutations lead to the abnormal accumulation of alpha-synuclein protein in the brain, forming aggregates called Lewy bodies, which are a hallmark of PD pathology.

**LRRK2 gene:** Another significant genetic risk factor for PD is the Leucine-Rich Repeat Kinase 2 (LRRK2) gene. Mutations in this gene are associated with both familial and sporadic forms of PD. The LRRK2 protein plays a role in regulating various cellular processes, including neuronal survival and synaptic function. Mutations in LRRK2 lead to increased kinase activity, which is believed to contribute to the degeneration of dopaminergic neurons in PD.

**GBA gene:** Mutations in the Glucocerebrosidase Gene (GBA) are linked to an increased risk of PD. GBA mutations are also associated with Gaucher's disease, a lysosomal storage disorder. The GBA protein is involved in the breakdown of cellular waste products and its dysfunction can lead to the accumulation of harmful substances within cells.

## Description

### Innovative therapies targeting genetic factors

As our understanding of the genetic basis of PD advances, researchers

are exploring innovative therapeutic strategies that target these genetic factors to slow down or even halt the progression of the disease [4]. These approaches offer hope for more effective treatments and potentially disease-modifying interventions.

**Gene silencing and editing:** Recent advancements in gene silencing and editing technologies, such as RNA interference (RNAi) and CRISPR-Cas9, have opened new avenues for treating genetic disorders. In the context of PD, these techniques could be used to selectively target and silence or edit genes implicated in the disease, such as SNCA or LRRK2. By reducing the expression of these genes or correcting their mutations, researchers aim to mitigate the underlying pathological processes.

**Precision medicine:** The concept of precision medicine involves tailoring treatments to an individual's unique genetic makeup and characteristics. In PD, precision medicine could involve identifying specific genetic mutations or variations that contribute to an individual's risk of developing the disease. By analyzing a patient's genetic profile, clinicians could prescribe treatments that are most likely to be effective for that individual, minimizing potential side effects and optimizing therapeutic outcomes.

**Neuroprotective strategies:** Insights into the molecular mechanisms of PD provided by genetic research have highlighted potential targets for neuroprotective interventions. Therapies aimed at promoting the clearance of alpha-synuclein aggregates, restoring cellular waste disposal mechanisms (as seen with GBA-related mutations), or modulating the activity of kinases like LRRK2 are being explored as ways to slow down disease progression.

**Stem cell therapies:** Induced Pluripotent Stem Cells (iPSCs) derived from patients' own cells can be differentiated into dopaminergic neurons in the laboratory. This technology offers a platform for studying the disease in a personalized manner and screening potential drug candidates [5]. Additionally, iPSC-derived neurons could be used for transplantation, replacing the lost dopaminergic neurons in PD patients and potentially restoring motor function.

## Conclusion

The unraveling of the genetic predisposition to Parkinson's disease has ushered in a new era of understanding and potential therapeutic interventions. While genetic factors contribute to a subset of PD cases, their impact on disease mechanisms has illuminated pathways that can be targeted for innovative therapies. Gene silencing, precision medicine, neuroprotective strategies and stem cell therapies are among the promising approaches being explored. These advancements hold the potential to transform the landscape of Parkinson's disease management, moving beyond symptom control to potentially slowing or modifying the disease's course. However, challenges such as delivery methods, ethical considerations and long-term safety must be carefully addressed as these therapies progress from the laboratory to clinical applications. With continued research and collaboration, the field is poised to make significant strides in unraveling the complexities of Parkinson's disease and developing effective treatments that improve the lives of patients and their families.

## References

1. Bisht, Indu, Rashmi K. Ambasta and Pravir Kumar. "An integrated approach to

\*Address for Correspondence: Priya Samuel, Department of Medicine, University of Kerala, Kerala, India, E-mail: priyasam@icloud.com

Copyright: © 2023 Samuel P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 02 May, 2023, Manuscript No. cmcr-23-109742; Editor assigned: 03 May, 2023, PreQC No. P-109742; Reviewed: 01 June, 2023, QC No. Q-109742; Revised: 09 June, 2023, Manuscript No. R-109742; Published: 21 June, 2023, DOI: 10.37421/2684-4915.2023.7.271

- unravel a putative crosstalk network in Alzheimer's disease and Parkinson's disease." *Neuropeptides* 83 (2020): 102078.
2. Prasuhn, Jannik and Norbert Brüggemann. "Gene therapeutic approaches for the treatment of mitochondrial dysfunction in Parkinson's disease." *Genes* 12 (2021): 1840.
  3. Deal, Samantha L. and Shinya Yamamoto. "Unraveling novel mechanisms of neurodegeneration through a large-scale forward genetic screen in *Drosophila*." *Front Genet* 9 (2019): 700.
  4. Albrecht, Franziska, Konstantinos Poulakis, Malin Freidle and Hanna Johansson, et al. "Unraveling Parkinson's disease heterogeneity using subtypes based on multimodal data." *Parkinsonism Relat Disord* 102 (2022): 19-29.
  5. Doxakis, Epaminondas. "Insights into the multifaceted role of circular RNAs: Implications for Parkinson's disease pathogenesis and diagnosis." *NPJ Parkinsons Dis* 8 (2022): 7.

**How to cite this article:** Samuel, Priya. "Parkinson's disease Unravelling Genetic Predisposition and Innovative Therapies." *Clin Med Case Rep* 7 (2023): 271.